Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04332081 · ClinicalTrials.gov registry record · NA
Hyperbaric Oxygen for COVID-19 Patients
A NA study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT04332081 is a NA study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 80 participants.
The verdict
NCT04332081, a NA study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
Hyperbaric oxygen therapy (HBOT) treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patients with respiratory distress at NYU Winthrop Hospital. All patients prior to the clinical application of HBOT will be evaluated by the primary care team and hyperbaric physician. After the intervention portion of this study, a chart review will be performed to compare the outcomes of intervention patients versus patients who received standard of care.
Interventions
- DEVICE hyperbaric oxygen therapy (HBOT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2020-04-06 |
| Est. Completion | 2020-05-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04332081
The ClinicalTrials.gov registry entry for NCT04332081 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hyperbaric oxygen therapy (HBOT) is the first listed.
NCT04332081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04332081 about?
NCT04332081 is a clinical study titled "Hyperbaric Oxygen for COVID-19 Patients". Hyperbaric oxygen therapy (HBOT) treatment will be provided to patients as an adjunct to standard therapy for a cohort of 40 COVID19-positive patients with respiratory distress at NYU Winthrop Hospital. All patients prior to the clinical application of HBOT will be evaluated by the primary care team...
What is the current status of trial NCT04332081?
This trial is currently terminated. It is a NA study. The enrollment target is 80 participants. The study started on 2020-04-06. Estimated completion is 2020-05-29.
What interventions are being tested in trial NCT04332081?
The interventions under investigation include: hyperbaric oxygen therapy (HBOT) (DEVICE).
Who is sponsoring clinical trial NCT04332081?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.